ONCR-177

AXP000084.1 · Oncolytic virus

Platform
HSV-1 (microRNA-attenuated, ICP34.5 retained)
Originator
Oncorus
Sponsor
Oncorus

Names

NameTypeSource
ONCR-177preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
conditionally replicating
Modifications
microRNA target cassettes in ICP4, ICP27, UL8 and gamma34.5 transcripts; UL37 mutation; ICP47 deleted; ICP34.5 retained
Transgenes
IL12A, IL12B, CCL4, FLT3LG, anti-PD-1 antibody, anti-CTLA-4 antibody
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C171540
FDA UNII
83P3OQ67ZT

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04348916Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsTerminatedPhase 12020-05-202023-05-3166Advanced Solid Tumor; Breast Cancer; Cancer; Colorectal Carcinoma; Liver Metastases; Melanoma; Non-melanoma Skin Cancer; Solid Tumor; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 33355229ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.Cancer immunology research2021cited by trial NCT04348916

Notes

Attenuated by microRNA target cassettes rather than ICP34.5 deletion; carries five transgenes. Oncorus discontinued the programme in 2022 when it reprioritised to self-amplifying RNA.

How to cite

ONCR-177 (AXP000084.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000084.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.